Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
In brief
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors. PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy in treating patients with recurrent unresectable advanced solid tumors.
Key facts
- Study ID
- NCT00066651
- Run by
- National Cancer Institute (NCI)
- Starts
- 2003-07-01
- Last updated by the study team
- 2015-04-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
- Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.